Get the Stockscreener App
111.94
0.01%
-0.01
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr Stock (NVO) Forecast
The Novo Nordisk Adr (NVO) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $151.29, representing a +35.15% increase from the current price of $111.94. The highest analyst price target is $153.57, and the lowest is $149.00.
Note: Our forecast model does not currently account for dividend and stock split events. This means that our forecast may not be accurate for stocks that have recently experienced either of these events.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month NVO Price Target
Average 168.94
(+50.92% Upside)
Is Novo Nordisk Adr (NVO) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 30.68 | Neutral |
| STOCH(9,6) | 28.80 | Neutral |
| STOCHRSI(14) | 24.46 | Neutral |
| MACD(12,26) | -3.1882 | Buy |
| ADX(14) | 33.03 | Sell |
| William %R | -60.33 | Neutral |
| CCI(14) | -72.46 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
113.83
Sell
|
113.72
Sell
|
| MA20 |
115.99
Sell
|
116.01
Sell
|
| MA50 |
124.20
Sell
|
121.72
Sell
|
| MA100 |
130.32
Sell
|
125.86
Sell
|
| MA200 |
128.27
Sell
|
128.50
Sell
|
Buy: 0
Sell: 10
Neutral: 0
Summary: Sell
According to our latest analysis, NVO could be considered a Strong Sell, with 17 technical analysis indicators signaling 1 Buy signals, 11 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on NVO, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 30.68 indicates that NVO is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 28.8 indicates that NVO is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 24.46 indicates that NVO is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 33.03 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -72.46 indicates that NVO is still oversold but not to an extreme extent.
Long-term NVO price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Novo Nordisk Adr financial reports and earnings history, Novo Nordisk Adr (NVO) stock could reach $219.08 by 2030, $736.32 by 2040 and $900.11 by 2050. See the projected annual prices until 2050 of the Novo Nordisk Adr stock below:
- Novo Nordisk Adr (NVO) is expected to reach an average price of $513.38 in 2035, with a high prediction of $513.62 and a low estimate of $499.88. This indicates an $358.62% rise from the last recorded price of $111.94.
- Novo Nordisk Adr (NVO) stock is projected to chart a bullish course in 2040, with an average price target of $731.83, representing an $553.77% surge from its current level. The forecast ranges from a conservative $716.88 to a sky-high $736.32.
- Our analysts predict Novo Nordisk Adr (NVO) to jump 611.10% by 2045, soaring from $785.12 to an average price of $796.01, potentially reaching $798.38. While $785.12 is the low estimate, the potential upside is significant.
- Novo Nordisk Adr (NVO) stock is expected to climb by 2050, reaching an average of $900.11, a $704.10% jump from its current level. However, a wide range of estimates exists, with high and low targets of $900.11 and $883.37, respectively, highlighting the market's uncertainty.
Novo Nordisk Adr Stock (NVO) Year by Year Forecast
Novo Nordisk Adr Stock (NVO) Price Forecast for 2024
Our forecast for NVO stock price in 2024 now indicates an average price target of $127.64 with a high forecast of $153.57 and a low forecast of $101.71. The average prediction reflects an increase of +14.03% from the last recorded price of $111.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| December, 2024 | $152.93 | $149.00 | $153.57 | +36.62% |
Novo Nordisk Adr Stock (NVO) Price Forecast for 2025
Novo Nordisk Adr Stock (NVO) is expected to reach an average price of $173.35 in 2025, with a high prediction of $193.62 and a low estimate of $153.08. This indicates an +54.86% rise from the last recorded price of $111.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $155.67 | $153.08 | $156.89 | +39.06% |
| February, 2025 | $161.21 | $155.57 | $162.25 | +44.02% |
| March, 2025 | $159.58 | $159.51 | $166.14 | +42.56% |
| April, 2025 | $164.59 | $153.30 | $167.42 | +47.03% |
| May, 2025 | $170.72 | $163.05 | $171.36 | +52.51% |
| June, 2025 | $172.15 | $169.52 | $172.76 | +53.79% |
| July, 2025 | $178.12 | $170.71 | $178.60 | +59.12% |
| August, 2025 | $177.86 | $176.05 | $179.74 | +58.89% |
| September, 2025 | $178.96 | $177.44 | $182.30 | +59.87% |
| October, 2025 | $181.69 | $179.06 | $183.49 | +62.31% |
| November, 2025 | $187.86 | $181.51 | $188.89 | +67.82% |
| December, 2025 | $184.63 | $183.96 | $193.62 | +64.94% |
Novo Nordisk Adr Stock (NVO) Price Forecast for 2026
The predicted value for Novo Nordisk Adr (NVO) in 2026 is set at an average of $217.21. Estimates vary from a peak of $248.79 to a trough of $185.63, indicating an +94.04% surge from the present price of $111.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $190.13 | $185.63 | $193.23 | +69.85% |
| February, 2026 | $198.23 | $189.94 | $198.36 | +77.08% |
| March, 2026 | $198.32 | $194.23 | $198.58 | +77.16% |
| April, 2026 | $202.68 | $196.36 | $204.25 | +81.06% |
| May, 2026 | $200.80 | $197.44 | $203.23 | +79.38% |
| June, 2026 | $202.42 | $197.50 | $202.50 | +80.83% |
| July, 2026 | $213.71 | $202.05 | $214.08 | +90.91% |
| August, 2026 | $220.91 | $214.24 | $221.40 | +97.35% |
| September, 2026 | $225.31 | $218.87 | $225.99 | +101.28% |
| October, 2026 | $240.10 | $225.38 | $243.83 | +114.49% |
| November, 2026 | $242.44 | $240.64 | $248.79 | +116.58% |
| December, 2026 | $240.79 | $239.61 | $246.85 | +115.11% |
Novo Nordisk Adr Stock (NVO) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Novo Nordisk Adr (NVO) is $262.96, with a high forecast of $285.78 and a low forecast of $240.13. This indicates an +134.91% increase from the last price of $111.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $252.65 | $240.13 | $252.72 | +125.70% |
| February, 2027 | $262.35 | $252.54 | $264.17 | +134.37% |
| March, 2027 | $258.24 | $255.61 | $268.14 | +130.70% |
| April, 2027 | $248.96 | $248.01 | $264.63 | +122.41% |
| May, 2027 | $254.16 | $245.08 | $261.66 | +127.05% |
| June, 2027 | $260.91 | $250.63 | $264.13 | +133.08% |
| July, 2027 | $269.70 | $257.75 | $272.37 | +140.94% |
| August, 2027 | $271.20 | $270.50 | $282.00 | +142.28% |
| September, 2027 | $270.55 | $264.51 | $277.10 | +141.70% |
| October, 2027 | $270.24 | $268.90 | $280.98 | +141.42% |
| November, 2027 | $275.54 | $272.16 | $279.36 | +146.15% |
| December, 2027 | $276.33 | $267.73 | $285.78 | +146.85% |
Novo Nordisk Adr Stock (NVO) Price Forecast for 2028
In 2028, Novo Nordisk Adr (NVO) is projected to reach an average price of $314.79, with a high projection of $362.04 and a low estimate of $267.54. This indicates an +181.22% rise from the last price of $111.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $272.92 | $271.37 | $281.56 | +143.81% |
| February, 2028 | $272.15 | $267.54 | $281.88 | +143.13% |
| March, 2028 | $283.68 | $274.23 | $284.03 | +153.42% |
| April, 2028 | $295.48 | $281.24 | $295.78 | +163.96% |
| May, 2028 | $313.00 | $296.69 | $313.73 | +179.61% |
| June, 2028 | $321.95 | $310.49 | $321.96 | +187.61% |
| July, 2028 | $322.24 | $313.40 | $326.09 | +187.87% |
| August, 2028 | $326.30 | $321.62 | $330.95 | +191.49% |
| September, 2028 | $346.22 | $320.79 | $347.77 | +209.29% |
| October, 2028 | $351.95 | $344.27 | $360.75 | +214.41% |
| November, 2028 | $348.16 | $345.37 | $362.04 | +211.02% |
| December, 2028 | $354.70 | $347.32 | $355.11 | +216.87% |
Novo Nordisk Adr Stock (NVO) Price Forecast for 2029
The 2029 price forecast for Novo Nordisk Adr Stock (NVO) is $304.81 on average, with a high prediction of $400.64 and a low estimate of $208.98. This represents an +172.30% increase from the previous price of $111.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $356.28 | $344.91 | $360.80 | +218.28% |
| February, 2029 | $383.46 | $352.03 | $388.29 | +242.56% |
| March, 2029 | $389.31 | $382.33 | $400.64 | +247.78% |
| April, 2029 | $302.87 | $287.23 | $388.00 | +170.56% |
| May, 2029 | $304.23 | $294.59 | $306.29 | +171.78% |
| June, 2029 | $305.29 | $299.50 | $309.87 | +172.73% |
| July, 2029 | $310.19 | $300.55 | $311.73 | +177.10% |
| August, 2029 | $323.79 | $308.91 | $325.17 | +189.26% |
| September, 2029 | $334.35 | $322.75 | $335.77 | +198.69% |
| October, 2029 | $341.97 | $330.27 | $350.57 | +205.50% |
| November, 2029 | $337.77 | $336.85 | $343.93 | +201.74% |
| December, 2029 | $210.19 | $208.98 | $346.58 | +87.77% |
Novo Nordisk Adr Stock (NVO) Price Forecast for 2030
Novo Nordisk Adr Stock (NVO) is expected to reach an average price of $240.07 in 2030, with a high forecast of $270.79 and a low forecast of $209.34. This signifies an +114.46% surge from the last price of $111.94.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $217.58 | $209.34 | $219.08 | +94.38% |
| February, 2030 | $217.87 | $217.52 | $221.93 | +94.63% |
| March, 2030 | $222.75 | $218.44 | $222.87 | +98.99% |
| April, 2030 | $229.65 | $222.69 | $230.48 | +105.15% |
| May, 2030 | $233.99 | $228.15 | $234.84 | +109.03% |
| June, 2030 | $240.15 | $232.72 | $240.36 | +114.53% |
| July, 2030 | $245.01 | $240.93 | $248.00 | +118.87% |
| August, 2030 | $252.26 | $247.21 | $252.79 | +125.35% |
| September, 2030 | $256.74 | $252.87 | $257.08 | +129.36% |
| October, 2030 | $266.03 | $257.70 | $266.53 | +137.66% |
| November, 2030 | $262.25 | $259.69 | $270.12 | +134.28% |
| December, 2030 | $269.69 | $256.93 | $270.79 | +140.92% |
0.16%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):